The Medicare Bridge Copay Structure: What Beneficiaries Actually Pay

The Bridge Program at a Glance

On July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge — a temporary demonstration program that gives eligible Medicare Part D beneficiaries access to select GLP-1 weight-loss medications for a flat $50 monthly copayment. The program runs through December 31, 2027.

This is a seismic shift. Medicare has historically been prohibited by statute from covering drugs used for weight loss. The Bridge program is a time-limited workaround, testing whether providing this access reduces long-term Medicare spending through improved health outcomes.

What the $50 Copay Covers

The Bridge program covers three FDA-approved GLP-1 medications when used specifically for weight reduction and maintenance:

The $50 copay is flat and does not change based on dose, formulation, or how many months you have been on the program. Whether you are on Wegovy 0.25mg in your first month or Zepbound 15mg in month twelve, you pay $50.

Who Qualifies

Eligibility requires meeting all of the following criteria:

Enrollment Requirements

• Medicare Part D coverage — either through a standalone PDP or a Medicare Advantage plan (MA-PD) that includes drug coverage. Beneficiaries in SNPs, EGWPs, and the LI NET program are also eligible.
• Age 18 or older
• Prior authorization from the Bridge Program's central processor (not your Part D plan)

Clinical Criteria

You must meet one of these weight and health combinations:

Who Does NOT Qualify

• Beneficiaries already receiving a GLP-1 through their Part D plan
• Beneficiaries with a diagnosis of type 2 diabetes (covered separately through Part D)
• Beneficiaries with moderate-to-severe sleep apnea (also covered through Part D for some GLP-1s)
• Beneficiaries with non-alcoholic steatohepatitis / fatty liver disease

How the $50 Copay Works (Mechanically)

The Bridge program operates outside the standard Part D benefit structure. This has several important implications:

• Your $50 does NOT count toward your Part D deductible. It is a separate payment stream entirely.
• Your $50 does NOT count toward your Part D out-of-pocket maximum ($2,100 in 2026, $2,400 in 2027).
• Your Part D plan does not bear any financial risk for Bridge medications. CMS pays the pharmacy directly after collecting the negotiated net price from manufacturers.
• Low-Income Subsidy (LIS) cost-sharing reductions do NOT apply to Bridge copays. This means low-income beneficiaries who normally pay $0–$11 for Part D medications will owe the full $50 for Bridge medications.

That last point is significant and has drawn criticism. For beneficiaries on fixed incomes, $50/month may still be unaffordable — even though it represents a 96% discount from Wegovy's retail price.

What the Program Costs the Government

CMS negotiated a net price of approximately $245/month per beneficiary with Novo Nordisk and Eli Lilly. Of that, beneficiaries pay $50 (their copay), and CMS covers the remaining $195. The program's viability hinges on whether the $195/month government subsidy generates enough downstream healthcare savings — through reduced cardiovascular events, fewer diabetes diagnoses, and lower hospitalization rates — to offset the cost.

How to Enroll

1. Talk to your doctor. Your prescriber initiates the process by prescribing an eligible GLP-1 medication for weight management and submitting the prior authorization to the Bridge Program's central processor.
2. Central processor reviews. CMS uses a single national processor (not your Part D plan) to manage prior authorization, claims adjudication, and pharmacy payment.
3. Fill at your pharmacy. Once authorized, you fill the prescription at a participating pharmacy and pay the $50 copay.
4. Refill monthly. The authorization is ongoing for the program's duration (through December 31, 2027), subject to continued eligibility.

Bridge vs. Compounded: The Cost Comparison

For eligible Medicare beneficiaries, the Bridge program is almost certainly the best financial option:

At $50/month for FDA-approved brand-name medication, the Bridge program beats every compounded alternative on both price and regulatory status. If you qualify, it is the clear winner.

What Happens After December 2027?

The Bridge program is explicitly temporary. CMS has indicated it may transition into the BALANCE Model — a longer-term Medicare Part D demonstration that would integrate GLP-1 weight-loss coverage into the standard benefit structure. But BALANCE is not guaranteed, and its design is still being finalized.

If the Bridge ends without a successor program, beneficiaries will lose access to $50 GLP-1s and face three options: pay full retail/self-pay prices for brand-name medications, switch to compounded alternatives if available, or discontinue treatment. This uncertainty is worth factoring into your treatment planning — starting GLP-1 therapy with a plan for what happens at the 18-month mark.

For beneficiaries who do not qualify for the Bridge program or need a provider to coordinate the prescription, Sesame Care specializes in brand-name FDA-approved GLP-1 prescriptions and may be able to assist with Bridge enrollment paperwork.

The Bottom Line

The Medicare GLP-1 Bridge program is the most significant development in GLP-1 affordability for seniors in 2026. At $50/month for FDA-approved Wegovy, Zepbound (KwikPen), or Foundayo, it eliminates the cost barrier for millions of eligible beneficiaries. The program's limitations — temporary duration, LIS exclusion, narrow clinical criteria — are real but do not diminish the value for those who qualify. If you are a Medicare beneficiary with a BMI ≥ 27 (plus a qualifying condition) or ≥ 35, talk to your doctor about enrollment now.